argenx SE (ARGX) Q2 FY25 earnings call

argenx delivered a strong second quarter, driven by exceptional growth in VYVGART sales and patient adoption across all indications and formulations, particularly with the successful introduction of the prefilled syringe. The company continues to advance a robust pipeline with multiple assets in late-stage development, reinforcing its long-term growth strategy. While navigating anticipated gross-to-net increases and monitoring a potential safety signal for CIDP, management remains focused on market expansion and innovation.